论文信息 - Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). - 字舞流文

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).

Emily C. O'Brien | C. Yancy | W. Laskey | P. Heidenreich | G. Fonarow | B. Hammill | L. Curtis | Adrian F. Hernandez | Melissa A. Greiner | E. O'Brien | S. Lippmann | R. Mentz | Xiaojuan Mi | S. Turner | Steven J. Lippmann | N. Luo | N. C. Hardy

[1] S. Solomon,et al. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. , 2016, JAMA cardiology.

[2] S. DeKosky,et al. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. , 2016, JAMA.

[3] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[4] Alastair Baker,et al. Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.